Advances in multiple myeloma therapy during two past decades

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10291741" target="_blank" >RIV/00216208:11110/14:10291741 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10291741

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.csbj.2014.05.005" target="_blank" >http://dx.doi.org/10.1016/j.csbj.2014.05.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.csbj.2014.05.005" target="_blank" >10.1016/j.csbj.2014.05.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Advances in multiple myeloma therapy during two past decades

Popis výsledku v původním jazyce

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of plasma cells within bone marrow and extramedullary sites. It is one of the most common haematological malignancies; it accounts for 1.4% of all tumours and is responsible for 2% of cancer-related mortality. Over the last decades, the paradigm of MM therapy has changed dramatically - from the conventional combination of oral melphatan + prednisone, high-dose chemotherapy with stem cell (ASCT) support for younger patients to the present paradigm with the use of one (or more) of 3 major new targeted agents - the first-in class proteasome inhibitor bortezomib, the immunomodulatory drug thalidomide, and its more potent derivative lenalidomide. Their use as a part of initial therapy is associated with high overall response rates as well as high rates of complete response (CR), both for elderly patients unable to undergo ASCT and for younger patients treated prior to ASCT. Altogether, the advent of nove

Název v anglickém jazyce

Advances in multiple myeloma therapy during two past decades

Popis výsledku anglicky

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of plasma cells within bone marrow and extramedullary sites. It is one of the most common haematological malignancies; it accounts for 1.4% of all tumours and is responsible for 2% of cancer-related mortality. Over the last decades, the paradigm of MM therapy has changed dramatically - from the conventional combination of oral melphatan + prednisone, high-dose chemotherapy with stem cell (ASCT) support for younger patients to the present paradigm with the use of one (or more) of 3 major new targeted agents - the first-in class proteasome inhibitor bortezomib, the immunomodulatory drug thalidomide, and its more potent derivative lenalidomide. Their use as a part of initial therapy is associated with high overall response rates as well as high rates of complete response (CR), both for elderly patients unable to undergo ASCT and for younger patients treated prior to ASCT. Altogether, the advent of nove

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12215" target="_blank" >NT12215: Racionalizace léčby mnohočetného myelomu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Computational and Structural Biotechnology Journal

ISSN

2001-0370

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

16

Stát vydavatele periodika

SE - Švédské království

Počet stran výsledku

3

Strana od-do

38-40

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—